The use of base editing to generate universal off-the-shelf CAR T cells induced durable remissions -- up to 36 months in one ...

Higher levels of CD4-positive naïve T cells in patients receiving CAR T-cell therapy for multiple myeloma are associated with ...

Data presented at ASH 2025 suggest earlier-line use of cilta-cel leads to better outcomes in multiple myeloma because patients have fitter immune systems and less exhausted T cells, improving CAR T ...

Colleen Mabasa, a patient with multiple myeloma, discusses her CAR T-cell therapy journey and the pivotal role self-advocacy ...

The EVEREST-2 study reported the first complete response to CAR-T cell therapy in a non-small cell lung cancer patient.

Improved QOL is observed in patients over two years post-infusion and those without disease progression, highlighting the ...

Immune cells are most commonly engineered to kill cancers, but now, scientists have shown the technique makes the gut lining ...

A blood cancer diagnosis comes with a lot of new information and confusion ranging from blood tests and medical terminology to healthcare provider conversations and treatment considerations. Here’s ...

Multiple myeloma, a cancer of the bone marrow, remains difficult to treat despite modern CAR T cell therapies. In recent research, a team led by Dr. Armin Rehm presents an improved immunotherapy that ...

For the first time, researchers at the University of British Columbia have demonstrated how to reliably produce an important type of human immune cell—known as helper T cells—from stem cells in a ...

Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, ...